SCA
ALXN

Strategic Capital Alternatives’s Alexion Pharmaceuticals ALXN Stock Holding History

Strategic Capital Alternatives’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-440
Closed -$80K – 509
2015
Q2 		$80K Buy
+440
New +$75.9K 0.02% 260
2014
Q4 		– Sell
-440
Closed -$73K – 369
2014
Q3 		$73K Buy
+440
New +$72.3K 0.03% 195

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Strategic Capital Alternatives's ALXN Position: Q3 2015 in Review

Strategic Capital Alternatives sold out of Alexion Pharmaceuticals (ALXN) in Q3 2015, closing a stake of 440 shares — an estimated $80K sold.

Strategic Capital Alternatives first reported a position in ALXN in Q3 2014 and held it in 2 quarters. The position peaked at $80K in Q2 2015. 515 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

  • Strategic Capital Alternatives reported no remaining Alexion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Strategic Capital Alternatives sold 440 Alexion Pharmaceuticals shares in Q3 2015, an estimated $80K.
  • Strategic Capital Alternatives first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Strategic Capital Alternatives's Alexion Pharmaceuticals position peaked at $80K in Q2 2015.
  • 515 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.